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ISObjectives: Zidovudine (AZT) is recommended for first-line antiretroviral therapy
(ART) in resource limited settings. AZT may, however, lead to anemia and impaired
immunological response. We compared CD4 counts over 5 years between patients
starting ART with and without AZT in Southern Africa.
Design: Cohort study.
Methods: Patients aged16 years who started first-line ART in South Africa, Botswana,
Zambia or Lesotho were included. We used linear mixed-effect models to compare
CD4 cell count trajectories between patients on AZT-containing regimens and patients
on other regimens, censoring follow-up at first treatment change. Impaired immuno-
logical recovery, defined as a CD4 count below 100cells/ml at 1 year, was assessed in
logistic regression. Analyses were adjusted for baseline CD4 count and haemoglobin
level, age, gender, type of regimen, viral load monitoring and calendar year.
Results: 72597 patients starting ART, including 19758 (27.2%) on AZT, were ana-
lysed. Patients on AZT had higher CD4 cell counts (150 vs.128 cells/ml) and haemo-
globin level (12.0 vs. 11.0 g/dl) at baseline, and were less likely to be female than those
on other regimens. Adjusted differences in CD4 counts between regimens containing
and not containing AZT were -16 cells/ml (95% CI18 to14) at 1 year and56cells/
ml (95% CI 59 to 52) at 5 years. Impaired immunological recovery was more likely
with AZT compared to other regimens (odds ratio 1.40, 95% CI 1.22–1.61).
Conclusions: In Southern Africa AZT is associated with inferior immunological recov-
ery compared to other backbones. Replacing AZT with another NRTI could avoid
unnecessary switches to second-line ART.
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In low-income countries, the World Health Organization
(WHO) recommends the use of standardized first-line
antiretroviral therapy (ART) consisting of one non-
nucleoside reverse transcriptase inhibitor (NNRTI) and
two nucleoside reverse transcriptase inhibitors (NRTI) [1].
At present the two preferred backbones are lamivudine
(3TC) or emtricitabine (FTC)þ tenofovir (TDF) or 3TC
þ zidovudine (AZT). Although the efficacy and toxicityof
these regimens have been studied extensively in clinical
trials in high-income countries, data on long-term clinical
outcomes in Sub-Saharan Africa are scarce.
A concern with the use of AZT is its well-known
myelosuppressive effect, sometimes leading to severe
hematologic toxicity [2,3]. AZT-related anaemia has been
described in many studies, including in reports from sub-
Saharan Africa [4,5]. As a consequence, most ART
guidelines have precluded its use in patients with severe
anaemia. The impaired immunological recovery related
to the use of AZT has also been reported in clinical trials
and observational studies, both in industrialized countries
[6–11] and sub-Saharan Africa [12,13]. However, these
studies were small and had limited follow-up time. In
southern Africa, most of the HIV-infected patients are
treated in settings where viral load monitoring is not
available and are thus switched to second-line regimens
according to clinical and immunological criteria. Several
studies, including analyses from the International
epidemiologic Databases to Evaluate AIDS (IeDEA)
[14–16], have described risk factors for impaired
immunological response to ART, but only few publi-
cations have examined the role of specific antiretroviral
drugs in sub-Saharan Africa. To avoid unnecessary
switching to expensive protease inhibitor (PI)-based
second-line ART, a better understanding of the factors
impairing immunological recovery is needed.
We compared 5-year CD4 cell count trajectories after
ART initiation between patients on first-line regimen
containing AZTand those not receiving AZTand assessed
the association between AZT and severe impairment of
immunological recovery in a large collaborative analysis of
nine cohorts in four countries in southern Africa.Methods
Antiretroviral treatment programmes
The International epidemiological Databases to Evaluate
AIDS in Southern Africa (IeDEA-SA) is a largepincott Williams & Wilkins. Unauthocollaboration of ART programmes in southern Africa
[17]. Data are collected at ART initiation (baseline) and
each follow-up visit, using standardized instruments, and
transferred to data centres at the Universities of Cape
Town, Republic of South Africa (RSA) and Bern,
Switzerland. All sites have ethical approval to collect data
and to participate in IeDEA-SA.
We included all cohorts with at least 100 adult patients in
both treatment groups (with and without AZT). Six ART
programmes in RSA and one in Botswana monitored
viral load and CD4 cell counts every 6 months during the
first year of ART, and then yearly: Aurum Institute
(community and workplace), Themba Lethu, Khayelit-
sha, Gugulethu, Tygerberg, in South Africa, as well as
Gaborone private clinic in Botswana. Two cohorts with
routine CD4 count but no viral load monitoring were
also included: the Ministry of Health - Centre for
Infectious Disease Research in Zambia (MoH-CIDRZ)
and the SolidarMed ART program in rural Lesotho. All
treatment programmes trace patients lost to follow-up.
Eligibility criteria
All patients aged 16 years and older who started a first-line
ART regimen and had at least 2 CD4 cell counts
performed (one at ART start and at least one during
follow-up) were included. We defined first-line regimens
according to theWHO treatment guidelines as a regimen
including an NNRTI and 2 NRTIs. Patients with prior
exposure to ART before inclusion in the treatment
program were excluded.
Outcomes
We compared CD4 trajectories between patients receiv-
ing a first-line regimen including AZT with those on
other ART combinations over the first 5 years of
treatment. Differences in CD4 cell counts after one and 5
years of ARTwere compared between patients receiving
AZT and those on other first-line ART regimens.
Follow-up was censored at the date of the first treatment
change, the last visit or the end of the study period,
whichever occurred first. In a second analysis we focused
on patients who started ART with severe immunodefi-
ciency, defined as a baseline CD4 cell count below
100 cells/ml. WHO included three specific criteria in the
definition of immunological treatment failure, one of
which being the persistence of a CD4 cell count below
100 cells/ml. We assessed the association between AZT
and impairment of immunological recovery, defined as a
CD4 count remaining below 100 cells/ml 1 year after the
initiation of ART.rized reproduction of this article is prohibited.
CE: Alpana; QAD/203449; Total nos of Pages: 9;
QAD 203449
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sStatistical analyses
Baseline characteristics of patients on AZT-containing
regimens were compared to those of patients not on AZT
using chi-squared and Mann-Whitney tests for categori-
cal and continuous variables, respectively. We used
multivariable linear mixed-effect models to analyse
CD4 cell count trajectories over the first 5 years of
ART, as described in detail elsewhere [16]. Differences in
CD4 cell counts after 1 and 5 years of ART were
compared between patients on AZT and not on AZT.
CD4 cell counts were square-root transformed and
trajectories modelled using fractional polynomials.
Results are presented as marginal CD4 estimates and
trajectories. Additionally, differences in CD4 cell counts
between the two treatment groups within each cohort
were described in a forest plot and overall estimates
obtained using random-effect meta-analysis. We repeated
all analyses in patients who remained virologically
suppressed during follow-up in South Africa and
Botswana and within each baseline CD4 cell count
category. Predictors of impairment of immunological
recovery during the first year of ART were evaluated
using multivariable logistic regression. For the latter
analysis, only patients who started a first-line ART
regimen with a CD4 cell count below 100 cells/ml and
with an available CD4 measurement between 8 and 15
months were included.
All multivariable analyses were adjusted for sex, age (16–
29, 30–39 or 40 years and over), CD4 cell count at
baseline (0–49, 50–99, 100–199, 200 cells/ml), calen-
dar year of starting first-line ART (before 2007, 2007,
2008, 2009 and 2010), degree of anaemia at baseline, type
of NNRTI (efavirenz or nevirapine) and viral load
monitoring (yes or no). Anaemia was defined as severe
(haemoglobin <5.0mmol/L), moderate (5.0–
<6.2mmol/L in women and 5.0–<6.8mmol/L in
men), mild (6.2–<7.4mmol/L in women and 6.8–
<8.1mmol/L in men) or none (7.4mmol/L in women
and8.1mmol/L in men). Multiple imputation was used
to impute missing haemoglobin values at baseline, with
analyses run on each of 20 datasets and results combined
with Rubin’s rules [18]. All analyses were performed
using Stata software version 11 (College Station, Texas,
USA).T
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.Results
ART programmes and patients characteristics
Table 1 shows the composition of cohorts. A total of
72 597 patients on first-line ART, including 19 758
(27.2%) on an AZT-containing regimen were included in
the analyses. The majority of patients were female in all
cohorts except for the AURUM workplace cohort in
South Africa, which was dominated by male miners. The
median age ranged from 33 years in Gugulethu andCopyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Table 2. Characteristics of patients at the start of first-line ART.
AZT No AZT P-value
(N¼19758) (N¼52839)
Female gender (%) 10320 (52.2) 33334 (63.1) <0.001
Median age at start (IQR) 36 (31–44) 36 (30–42) <0.001
Median CD4 count in cells/ml (IQR) 150 (85–212) 128 (63–195) <0.001
Median hemoglobin in g/dl (IQR) 12.0 (10.9–13.3) 11.0 (9.5–12.5) <0.001
missing (%) 2868 (14.5) 6606 (12.5)
Anemia <0.001
no (%) 7319 (43.3) 13106 (28.4)
mild (%) 7321 (43.4) 16074 (34.8)
moderate (%) 2112 (12.5) 13374 (28.9)
severe (%) 138 (0.8) 3679 (8.0)
Calendar year of first-line ART start (%) <0.001
Before 2007 11764 (59.5) 17869 (33.8)
2007 4295 (21.8) 9983 (18.9)
2008 2057 (10.4) 12079 (22.9)
2009-10 1642 (8.3) 12908 (24.4)
NNRTI (%) <0.001
NVP-based 13466 (68.2) 25028 (47.4)
EFV-based 6292 (31.8) 27811 (52.6)
NRTI (%)
3TC/D4T 0 33580 (63.6)
3TC/AZT 19722 (99,8) 0
XTC/TDF 0 18440 (34.9)
3TC/ABC 0 672 (1.2)
other 36 (0.2) 147 (0.3)
Virological monitoring (%) 6380 (32.3) 20533 (38.9) <0.001
Median follow-up time (days) 509 (224–967) 366 (197–639) <0.001
3TC, lamivudine; ABC, abacavir; AZT, zidovudine; D4T, stavudine; EFV, efavirenz; IQR, interquartile range; NVP, nevirapine; XTC, lamivudine or
emtricitabine. Anemia was categorized as follows: severe: haemoglobin <5.0mmol/L, moderate: 5.0–<6.2mmol/L in women and 5.0–
<6.8mmol/L in men, mild: 6.2–<7.4mmol/L in women and 6.8–<8.1mmol/L in men, none: 7.4mmol/L in women and 8.1mmol/L in
men; P values from chi-squared tests or Mann-Whitney tests.Khayelitsha to 43 years in the AURUM workplace
cohort. In South Africa, the proportion of patients on
AZT ranged from 2.8% in Thembalethu to 82.9% in the
AURUM workplace cohort, and outside South Africa,
this proportion ranged from 28.3% in the CIDRZ
program in Lusaka to 77.1% in Gaborone, Botswana.
Median CD4 count and haemoglobin levels at initiation
of ART ranged from 90 cells/ml (interquartile range
(IQR): 41–158) and 10.9 g/dl (9.6–12.1) in Khayelitsha
to 160 cells/ml (90–228) and 13.3 g/dl (11.8–14.5) in the
AURUM miners cohort, respectively. Data on baseline
haemoglobin level was overall missing for 13.1% of
patients.
Patients receiving AZTwere less likely to be female, to
have started ART in recent years and to be treated in the
Republic of South Africa or Botswana (Table 2). Median
baseline CD4 cell count (150 vs. 128 cells/ml, p< 0.001)
and haemoglobin level (12.0 vs. 11.0 g/dl, p< 0.001)
were higher in patients on AZT compared to those in the
other treatment group (Table 2). Severe anaemia was
present in 8.0% of patients initiating ART not containing
AZT and in 0.8% of patients receiving AZT (p< 0.001).
The most common ART combinations were 3TC/
AZT/NVP (68.0%) and 3TC/AZT/EFV (31.8%) in the
AZT group, and 3TC/D4T/NVP (34.3%), 3TC/D4T/
EFV (29.3%), FTC/TDF/EFV (20.5%), and FTC/TDF/
NVP (11.5%) in the non-AZT group.pyright © Lippincott Williams & Wilkins. UnauthoCD4 trajectories
The total follow-up time was 34,964 and 68,353 person-
years for the AZT and non-AZT groups, respectively.
Figure 1 shows CD4 trajectories over the first five years of
ART, by first-line treatment group. During follow-up,
CD4 cell counts were similar during much of the first year
on ART but substantial differences emerged from year 1
onwards. After 1 and 5 years of ART, patients on AZT
reached estimated CD4 counts of 301 cells/ml (95% CI:
299 to 302) and 386 cells/ml (383 to 389), whereas those
not on AZTreached CD4 cell counts of 317cells/ml (316
to 318) and 442 cells/ml (440 to 444), respectively.
Estimated differences were -16 CD4 cells/ml (95% CI:
-18 to -14) at 1 year and -56 CD4 cells/ml (52 to 59) at
5 years in favour of the group of patients not receiving
AZT (Web table 1, http://links.lww.com/QAD/A358).
Adjusted estimates of difference in CD4 cell count
between treatment groups for each cohort are shown in
Figure 2. One and 5 years after the initiation of ART,
most cohorts showed a higher absolute CD4 cell count in
patients not receiving AZT compared to those on AZT.
At each time point, only 3 out of 9 cohorts hadmarginally
higher CD4 cells counts in patients on AZT, but these
differences were not statistically significant. However,
there was substantial heterogeneity between cohorts in
both analyses (chi-squared test for heterogeneity: p¼ 0.01
at 1 year and p< 0.001 at 5 years).rized reproduction of this article is prohibited.
CE: Alpana; QAD/203449; Total nos of Pages: 9;
QAD 203449
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Fig. 1. Estimated CD4 trajectories in patients starting first-line ART with and without zidovudine (AZT). The dotted lines
indicate 95% confidence intervals.Several additional analyses were performed to examine
immunological recovery in subgroups of patients (Web
table 1, http://links.lww.com/QAD/A358). The differ-
ence between the treatment groups was most pronounced
in patients who started ARTwith a CD4 cell count below
100 cells/ml: -66 cells/ml (95% CI:72 to61) at 5 years
in comparing AZTwith no AZT. In RSA and Botswana,
where virological monitoring was available, a higher
proportion of patients on AZT had at least one detectable
viral load during follow-up compared to those not on
AZT (39% vs. 20%, p< 0.001). However, in analyses
restricted to patients who were fully suppressed 6 months
after the initiation of ART and who remained so during
the whole follow-up period, we found no difference in
CD4 cell count at 1 year between patients on AZT and
those not on AZT and a significant difference at 5 years
(difference 21 cells/ml, 95% CI: 29 to 14) (Web
table 1, http://links.lww.com/QAD/A358).Copyright © Lippincott Williams & Wilkins. UnautPredictors of impairment of immunological
recovery
This analysis was based on 14,529 patients who started
ARTwithCD4 counts below 100 cells/ml. The number of
imputed haemoglobinvalueswere 938 (15.1%) in theAZT
group and 1,137 (10.4%) in the other group. 407 patients
(11.4%)onAZTand914patients (8.3%)onother regimens
remained below 100 CD4cells/ml at 1 year (p< 0.001). In
multivariate logistic regression patients on AZTweremore
likely to experience severe impairment of immunological
recovery than those on other first-line regimens (adjusted
odds ratio (aOR) 1.40, 95% CI: 1.22 to 1.61) (Table 3).
When this analysis was repeated on the complete-case
dataset, the result was similar (aOR: 1.38, 95% CI: 1.19–
1.60, data not shown). Male patients, those older than 40
years as well as patients with very low CD4 cell counts
(<50 cells/ml) at start of ARTwere also at increased risk of
impaired immunological recovery (Table 3).horized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
CE: Alpana; QAD/203449; Total nos of Pages: 9;
QAD 203449
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Fig. 2. Adjusted differences in CD4 counts between patients on AZT and those not on AZT after 1 (panel A) and 5 years (panel B)
of ART, by cohort. I-squared (p value from test of heterogeneity): 1year (panel A): 58.7% (pU0.013); 5 years (panel B): 87.8%
(p<0.001). Analyses were adjusted for sex, age, CD4 and anemia at baseline, calendar year, type of NNRTI and viral load
monitoring.
CE: Alpana; QAD/203449; Total nos of Pages: 9;
QAD 203449
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Table 3. Predictors of severe impairment in immunological recovery (NU14529).
Univariable analysis Multivariable analysis
OR (95%CI) P-value OR (95%CI) P-value
AZT
No 1.0 <0.001 1.0 <0.001
Yes 1.42 (1.25–1.60) 1.40 (1.22–1.61)
Sex
Male 1.0 <0.001 1.0 <0.001
Female 0.49 (0.44–0.55) 0.56 (0.49–0.63)
Age category (years)
16–29 1.0 <0.001 1.0 0.01
30–39 1.28 (1.09–1.50) 1.11 (0.94–1.31)
>39 1.64 (1.39–1.94) 1.33 (1.12–1.58)
CD4 category (cells/ml)
50–99 1.0 <0.001 1.0 <0.001
1–49 1.93 (1.72–2.17) 2.00 (1.77–2.25)
Anemia
No 1.0 <0.001 1.0 <0.001
Mild 0.83 (0.72–0.97) 0.88 (0.76–1.02)
Moderate 0.73 (0.62–0.85) 0.77 (0.65–0.91)
Severe 0.45 (0.33–0.61) 0.56 (0.41–0.76)
Year of ART start
Before 2007 1.0 0.64 1.0 0.01
2007 1.08 (0.93–1.25) 1.20 (1.03–1.39)
2008 1.09 (0.93–1.27) 1.28 (1.08–1.52)
2009-10 1.07 (0.85–1.35) 1.40 (1.08–1.81)
NNRTI
NVP 1.0 <0.001 1.0 0.72
EFV 1.31 (1.17–1.47) 1.03 (0.89–1.19)
VL monitoring
No 1.0 <0.001 1.0 0.01
Yes 1.22 (1.09–1.37) 1.21 (1.04–1.41)
AZT, zidovudine; EFV, efavirenz; NNRTI, non-nucleoside reverse transcriptase inhibitor; NVP, nevirapine; VL, viral load. Anemia was categorized
as follows: severe: haemoglobin <5.0mmol/L, moderate: 5.0–<6.2mmol/L in women and 5.0–<6.8mmol/L in men, mild: 6.2–<7.4mmol/L in
women and 6.8–<8.1mmol/L in men, none: 7.4mmol/L in women and 8.1mmol/L in men. Multivaribale analysis adjusted for all variables
shown in table.Discussion
This study of nine ART programs and over 70 000
patients from four countries in southern Africa found that
AZT influenced the magnitude of the CD4 count
increase over the first 5 years of treatment. Patients
receiving AZT had lower CD4 cell counts at 1 and 5 years
and were more likely to remain severely immune
suppressed during the first year of treatment. The
difference in immunological recovery between patients
on AZT and those on other backbones was consistent
across baseline CD4 cell count categories and, to a lesser
extent, was also seen in the subset of patients who had an
undetectable viral load throughout the follow-up period.
Numerous studies from high income countries have
assessed predictors of CD4 count increase following ART
initiation [19–22]. Even though some individual
characteristics, including older age, lower baseline CD4
cell counts and hepatitis C virus co-infections have
consistently been shown to be associated with impaired
immunological recovery, there remains controversy on
the impact of specific ART components on CD4 cell
recovery [11]. In accordance with the results of two small
studies from Botswana and Cameroon [12,13], weCopyright © Lippincott Williams & Wilkins. Unautshowed that patients on AZT reached significantly lower
CD4 cell counts on ART compared to those on other
regimens. The reasons for the association of AZT with
impairment of total CD4 lymphocyte recovery are poorly
understood: the most probable explanation is related to
the well-known bone marrow suppression caused by
AZT [2–5]. Data from the Swiss HIV Cohort Study
showed reduced absolute but not relative CD4 counts in
patients on AZT, suggesting a general effect on total
lymphocyte count, rather than a CD4 specific effect [8].
Impaired immunological recovery in patients on ART
may not have important clinical consequences when it
concerns patients with high baseline CD4 counts.
However, in those with very low CD4 cell counts at
treatment initiation, failure to reach adequate cellular
immunity not only leads to an increased mortality and
HIV-associated morbidity, but also has important
implications on clinical decision-making: a CD4 cell
count persistently below 100 cells/ml is one of the three
criteria used to diagnose immunological failure (1). Thus,
in settings without access to viral load testing, many
patients who remain under this threshold during ARTare
switched to a PI-based regimen, despite possible
virological efficacy of the first-line regimen. In ourhorized reproduction of this article is prohibited.
Co
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severely immune suppressed after one year of ART
compared to those not receiving AZT. Even though in
our study the observed inferior virological efficacy of
AZT-containing regimens in RSAmight partially explain
the impaired immunological recovery in this group, we
found a difference in long-term CD4 recovery between
the 2 groups when the analyses were restricted to
virologically suppressed patients. This suggests that the
impact of AZT on immunological recovery is, to some
extent, independent of its virological efficacy.
Only few studies have compared outcomes between
different ART regimens in sub-Saharan Africa [23,24].
Our study is unique regarding its sample size and length of
follow-up: it involved a large number of patients from a
wide range of settings in southern Africa and described
immunological recovery over five years after the initiation
of ART. The main limitation of observational cohort data
comparing treatments in different countries lies in the
lack of randomization and the heterogeneity between the
treatment sites. Confounding by indication may have
affected our results: patients with advanced clinical disease
and low CD4 cell counts are also more likely to have
severe anemia, which is the main reason for not being
prescribed AZT. As a consequence, sicker patients are less
likely to receive AZT in many settings. This might have
led to an underestimation of the negative impact of AZT
on immunological recovery. Unfortunately, due to the
lack of data on pre-ART follow-up, causal modelling was
not possible. Furthermore, baseline haemoglobin levels
were missing in a substantial number of patients: although
we addressed this issue by using multiple imputation, the
missing data may have biased our results. A further
limitation of our study was the wide variation in the
proportion of patients on an AZT-containing regimen
across countries and calendar time. This issue was
described in detail in a previous multi-regional IeDEA
analysis [5] and most probably reflects national treatment
guidelines. Although the association between AZT and
impaired immunological recovery was fairly consistent
across most cohorts in our study, the results from a few
treatment programs differed substantially from the overall
estimates. Finally, we had no data on relative CD4 cell
counts (CD4 percentage), which could have given more
information on the mechanism of impaired immuno-
logical recovery under AZT-containing ART.
In conclusion, patients on first-line ART regimens
including AZT are at risk of inferior CD4 cell recovery
compared to those treated with other backbones.
Treatment failure in patients remaining severely immune
suppressed during the first year on AZT should be
confirmed, where possible, with viral load testing before
switching them to a second-line regimen. In patients with
impaired immunological recovery but adequate virolo-
gical response with an AZT-containing regimen, the
replacement of AZT by another NRTI might be anpyright © Lippincott Williams & Wilkins. Unauthoadequate therapeutic approach. Further studies evaluating
the role of specific ART components in immunological
recovery are needed, especially from settings where
virological monitoring and data on relative CD4 cell
counts (or percentage) are available.Acknowledgements
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